Nxera Pharma Co., Ltd. (TYO:4565)

Nxera Pharma Balance Sheet

Financials in millions JPY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	17,748	20,365	36,203	49,065	66,557	60,087
Cash & Short-Term Investments	17,748	20,365	36,203	49,065	66,557	60,087
Cash Growth	-46.21%	-43.75%	-26.21%	-26.28%	10.77%	50.19%
Accounts Receivable	6,975	7,730	6,695	5,064	2,462	2,138
Other Receivables	3,713	3,867	4,643	6,823	140	103
Receivables	10,688	11,597	11,338	11,887	2,602	2,241
Inventory	10,071	11,294	8,838	2,903	-	-
Prepaid Expenses	-	1,205	1,259	790	638	388
Other Current Assets	1,668	4	217	467	145	92
Total Current Assets	40,175	44,465	57,855	65,112	69,942	62,808
Property, Plant & Equipment	5,976	7,455	7,468	7,900	3,791	3,817
Long-Term Investments	3,114	2,919	4,550	3,308	1,801	6,145
Goodwill	25,274	25,838	25,693	24,623	15,306	-
Other Intangible Assets	53,042	49,230	51,911	52,291	8,577	24,215
Long-Term Deferred Tax Assets	4,800	4,879	4,021	3,964	-	-
Other Long-Term Assets	-	1	-	-	-	-
Total Assets	132,381	134,787	151,498	157,198	99,417	96,985

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	3,410	7,494	4,052	4,244	1,628	1,176
Accrued Expenses	-	568	1,250	-	400	570
Current Portion of Long-Term Debt	5,798	5,798	5,798	5,941	-	-
Current Portion of Leases	891	886	892	832	176	193
Current Income Taxes Payable	57	244	322	4,640	260	279
Current Unearned Revenue	-	2,224	3,141	1,388	1,450	785
Other Current Liabilities	4,168	286	177	140	178	4,188
Total Current Liabilities	15,101	17,500	15,632	17,185	4,092	7,191
Long-Term Debt	44,451	47,189	57,727	63,215	27,981	27,440
Long-Term Leases	2,489	3,506	3,483	3,985	1,577	1,638
Long-Term Deferred Tax Liabilities	1	-	1,857	1,490	2,922	2,706
Other Long-Term Liabilities	5,536	5,595	4,281	4,513	4,909	542
Total Liabilities	67,578	73,790	82,980	90,388	41,481	39,517

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	48,505	47,450	47,172	46,807	41,335	41,036
Additional Paid-In Capital	23,100	22,120	35,074	34,048	29,525	29,100
Retained Earnings	-14,332	-17,546	-20,942	-16,104	-8,911	-9,768
Treasury Stock	-1,253	-3	-3	-1	-1	-
Comprehensive Income & Other	8,783	8,976	7,217	2,060	-4,012	-2,900
Total Common Equity	64,803	60,997	68,518	66,810	57,936	57,468
Shareholders' Equity	64,803	60,997	68,518	66,810	57,936	57,468
Total Liabilities & Equity	132,381	134,787	151,498	157,198	99,417	96,985

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	54,406	57,379	67,900	73,973	29,734	29,271
Net Cash (Debt)	-36,658	-37,014	-31,697	-24,908	36,823	30,816
Net Cash Growth	-	-	-	-	19.49%	31.78%
Net Cash Per Share	-404.62	-410.01	-353.24	-301.85	445.85	375.78
Filing Date Shares Outstanding	91.38	90.49	89.9	89.45	81.92	81.52
Total Common Shares Outstanding	91.38	90.49	89.9	89.45	81.92	81.52
Working Capital	25,074	26,965	42,223	47,927	65,850	55,617
Book Value Per Share	709.19	674.04	762.15	746.93	707.20	704.97
Tangible Book Value	-13,513	-14,071	-9,086	-10,104	34,053	33,253
Tangible Book Value Per Share	-147.88	-155.49	-101.07	-112.96	415.67	407.92
Order Backlog	-	1,929	1,122	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 24, 2026

Data Sources Report a data error